Arbutus Biopharma Corporation Company
Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus ("HBV") infection.
Industry:
Genomic and Epigenominc Instabillity
Headquarters:
United States
Register and Claim Ownership